So all patients uptake of LL can be different ??? According to the individuals CCR5 numbers ??? So the population most helped could be narrowed down to the patient population that would be most helped . Is that what your getting at ??

“”But if CD12 is squishy because mortality reduction comes in at 20%, the rock solid CCR5 RO results would be very helpful to push the FDA over the fence. “”